HIMS

Hims & Hers Health, Inc. (HIMS) | Rumor.io

Hims & Hers Health

HIMS

Attention (50-day avg)0.29%

Attention rank (50-day avg)#50

Bullish sentiment (50-day avg)83%

Price to earnings ratio57.1

Market capitalization6.7B

Earnings per share-0.64

Dividend yield (TTM)—

Revenue (annual)2.3B

Net income (annual)128.4M

Social

What share of all stock conversation is about HIMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.17% +0.1	0.28% +0.11	0.31% -0.03	0.46% -0.31

Sep 29

The company has seen a year-over-year increase of $84.5M in US quarterly revenue.
The stock has the potential to print a double-digit candle and the Elliot Wave charts will disappear, according to market analysts.
If the stock reaches its old high of $65, a $25,000 investment at $40 could result in a 63% return.

Generated by AI

Sentiment

Of the messages about HIMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.43% +35.81	88.9% +4.47	87.03% +8.15	75.13% -6.87
Bearish	2.57% -35.81	11.1% -4.47	12.97% -8.15	24.87% +6.87

Bullish· Sep 29

The company has consistently demonstrated strong revenue growth, increasing from $271M to $2.6B in just 5 years, with analysts expecting it to reach $4.5B by 2028.
The company's subscriber/ARPU (average revenue per user) model is undervalued, with Q3 subscribers at 3.191M and ARPU at $100, suggesting potential for future growth.
A breakout above the red trend-line could signal a significant price increase, making the stock an attractive investment opportunity for those who are patient and willing to take on some risk.

Bearish· Sep 23

The stock has lost its floor and may move down to $28.50 in the coming days.
The company's margin compression is real and may lead to further losses, with gross margin decreasing from 76% to 64%, net income turning from $42.5M to -$86.3M, and adjusted EBITDA decreasing from $82.2M to $60.3M.
The stock is experiencing heavy rejection from a resistance area, strongly favoring a target of $23 region next, with the closest key support level to watch being the VWAP currently at $23.

Generated by AI

Topics

Of the messages about HIMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	41.46%	7.42%	13.03%	10.11%
Announcements	1.95%	26.56%	19.38%	8.79%
Analysts	0%	12.23%	15.45%	23.17%
Technical Analysis	49.27%	40.64%	35.77%	9.43%
Macro	5.85%	12.95%	14.75%	46.12%
Controversies	1.46%	0.21%	1.61%	2.38%

Earnings· Aug 11

$HIMS reported Q2 revenue of $753.2M, up 38% YoY, with a GAAP loss of $0.37 per share versus the $0.05 loss expected.
The market is focused on the large profit miss and weaker margins, especially as HIMS shifts from high-margin compounded GLP-1s to lower-margin branded weight-loss products.
Despite the revenue beat and raised FY guidance, the stock is down 7% pre-market due to concerns about the company's profit outlook and declining gross margins.

Analysts· Jul 1

Bank of America raised its price target for Hims & Hers Health to $36 from $25, maintaining a Hold rating.
Canaccord Genuity raised its price target for Hims & Hers Health to $40 from $32, maintaining a Buy rating.
Analysts are upgrading their price targets for Hims & Hers Health due to improving prescription trends, growing demand for GLP-1 treatments, and continued enthusiasm, with two firms raising targets while the stock was already rising.

Announcements· Aug 11

Hims & Hers Health, Inc. (HIMS) reported Q2 revenue of $753.2M, a 38% YoY increase, beating expectations and adding 300,000 new subscribers.
The company's international business is expanding, with the U.K., Australia, and Germany each generating more than $100M in annualized revenue, and Canada on track to join this group.
HIMS raised its full-year revenue guidance to $3.1-$3.3B, driven by the Eucalyptus acquisition and strong growth in its weight-loss business, but also reported a net loss of $0.37/share due to declining gross margins.

Controversies· Jul 30

The FTC has sued Hims & Hers Health for alleged privacy and billing practices, with the company claiming the claims are baseless and planning to fight them.
Hims & Hers has been under FTC investigation for years, with the investigation becoming a lawsuit yesterday, and the company's disclosure of this information may have contributed to its stock price drop.
The lawsuit against Hims & Hers may be an overhang on the stock, with the FTC alleging that the company shared sensitive health data with advertisers without proper consent.

Macro· May 12

Hims & Hers Health reported Q1 2026 earnings with a significant miss on revenue and EPS, but the company's underlying story is a massive strategic shift toward branded GLP-1 medications.
The company's telehealth growth story is over, replaced by a narrative of rising customer acquisition costs, declining revenue per user, and margin compression.
Despite missing earnings estimates, the company's revenue and subscriber growth suggest a potential turnaround in 2026, but market sentiment currently ignores this narrative.

Technical Analysis· Aug 19

$HIMS is approaching a test of the 50 WMA at a time when the weekly moving averages are starting to squeeze, and a big move is coming for this stock, with a move above $33 potentially triggering a rapid move higher.
The stock is currently basing around the yearly-low AVWAP, where it meets the curved trendline, and is squeezed between two big levels pulling opposite ways, with $30 being the biggest calming node.
$HIMS has been in a bullish trend, breaking above the $30 level after a strong move, and is expected to continue moving higher, but patience is required, as great companies can still test one's conviction, and volatility is part of the game.

Generated by AI

Community

Of the messages about HIMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.73%	76.7%	43.96%	68.1%
Newcomers	12.27%	23.3%	56.04%	31.9%

Regulars· Sep 29

The biology revolution is expected to be delivered through Hims & Hers Health, Inc. ($HIMS), with many regulars holding onto their shares despite recent price swings.
Hims & Hers Health, Inc. ($HIMS) has reported a year-over-year increase of $84.5M in US quarterly revenue, with some arguing that the business has strong demand.
The subscriber/ARPU (average revenue per user) model for Hims & Hers Health, Inc. ($HIMS) has been updated, showing a Q3 subscriber count of 3.191M and an ARPU of $100, but with challenges in modeling and backtesting due to recent additions and relaunches.

Newcomers· Sep 29

Newcomers are excited about the potential for $HIMS to become a popular "memecoin" due to its stock price movement and pairing with other assets.
Fresh contract wins and revenue traction are being watched closely by newcomers, who are optimistic about the company's ability to scale and convert these wins into recognized revenue.
Newcomers are also discussing the long-term biology angle and how $HIMS is a direct way to play this theme, with some expressing interest in the company's ability to execute and convert its backlog into revenue.

Generated by AI

Key Stats for HIMS Stock52-Week Range: $14 to $65Market Cap: around $6. 9 billionStreet Mean Target: around $31Forward 2-Year Revenue Growth (CAGR): around 30%Forward 2-Year EPS Growth (CAGR): around 18%NTM P/E: around 23xLTM Gross Margin: 69.

1d agoYahoo Finance

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit

2d agoMorningstar

Can Hims & Hers Health (HIMS) Stay Cheap As Sales Face Scrutiny?

Hims & Hers Health has delivered a very strong multi year share price move, and that run now puts fresh attention on whether the current valuation can be supported by its sales base. With recent headlines around new products and regulatory scrutiny, the question is how much of that is already reflected in what investors are paying for each dollar of revenue. Over the past 3 years, Hims & Hers Health has returned about 3.7x for shareholders, which puts significant weight on whether its...

3d agoYahoo Finance

Hims & Hers CFO Okupe sells $876,846 of HIMS stock

3d agoInvesting.com

Also Discussed

Investors talking about HIMS also mention

#	Name	Attention
1	Oscar Health, Inc.OSCR	0.05%+0.02
2	Novo Nordisk A/S Sponsored ADRNVO	0.14%-0.03
3	LifeMD, Inc.LFMD	0%0
4	Duolingo, Inc. Class A Common StockDUOL	0%-0.01
5	Celsius Holdings IncCELH	0.01%-0.06
6	AST SpaceMobile Inc.ASTS	2.36%+0.89
7	Eli Lilly and CompanyLLY	0.15%+0.07
8	Super Micro Computer Inc.SMCI	0.1%+0
9	IREN Ltd.IREN	1.1%-0.14
10	Zeta Global Holdings Corp.ZETA	0%-0.03

Hims & Hers Health, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc. is a consumer-focused digital health and wellness company that operates a multi-specialty telehealth platform. The firm connects individuals with licensed healthcare professionals through its websites and mobile applications, enabling convenient access to medical consultations and, when appropriate, prescription therapies and personalized treatment plans. Its platform spans key areas such as sexual health, hair care, dermatology, mental health, hormone and primary care, and weight loss, complemented by comprehensive laboratory testing and curated non-prescription wellness products, supplements, and personal care items. Hims & Hers Health, Inc. uses a direct-to-consumer, largely subscription-based model, with medications fulfilled via licensed pharmacies and over-the-counter products sold through its digital storefronts. The company serves customers primarily in the United States, with additional reach in markets such as the United Kingdom and Canada, positioning itself as an accessible, digital-first alternative to traditional healthcare for adults seeking discreet and convenient care. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers Health, Inc. today plays a notable role in the telehealth and online pharmacy segments of the healthcare market.

Website

Location

2269 Chestnut Street

San Francisco, CA, 94123

United States

Social

What share of all stock conversation is about HIMS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.17% +0.1	0.28% +0.11	0.31% -0.03	0.46% -0.31

Sep 29

The company has seen a year-over-year increase of $84.5M in US quarterly revenue.
The stock has the potential to print a double-digit candle and the Elliot Wave charts will disappear, according to market analysts.
If the stock reaches its old high of $65, a $25,000 investment at $40 could result in a 63% return.

Generated by AI

Sentiment

Of the messages about HIMS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	97.43% +35.81	88.9% +4.47	87.03% +8.15	75.13% -6.87
Bearish	2.57% -35.81	11.1% -4.47	12.97% -8.15	24.87% +6.87

Bullish· Sep 29

The company has consistently demonstrated strong revenue growth, increasing from $271M to $2.6B in just 5 years, with analysts expecting it to reach $4.5B by 2028.
The company's subscriber/ARPU (average revenue per user) model is undervalued, with Q3 subscribers at 3.191M and ARPU at $100, suggesting potential for future growth.
A breakout above the red trend-line could signal a significant price increase, making the stock an attractive investment opportunity for those who are patient and willing to take on some risk.

Bearish· Sep 23

The stock has lost its floor and may move down to $28.50 in the coming days.
The company's margin compression is real and may lead to further losses, with gross margin decreasing from 76% to 64%, net income turning from $42.5M to -$86.3M, and adjusted EBITDA decreasing from $82.2M to $60.3M.
The stock is experiencing heavy rejection from a resistance area, strongly favoring a target of $23 region next, with the closest key support level to watch being the VWAP currently at $23.

Generated by AI

Topics

Of the messages about HIMS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	41.46%	7.42%	13.03%	10.11%
Announcements	1.95%	26.56%	19.38%	8.79%
Analysts	0%	12.23%	15.45%	23.17%
Technical Analysis	49.27%	40.64%	35.77%	9.43%
Macro	5.85%	12.95%	14.75%	46.12%
Controversies	1.46%	0.21%	1.61%	2.38%

Earnings· Aug 11

$HIMS reported Q2 revenue of $753.2M, up 38% YoY, with a GAAP loss of $0.37 per share versus the $0.05 loss expected.
The market is focused on the large profit miss and weaker margins, especially as HIMS shifts from high-margin compounded GLP-1s to lower-margin branded weight-loss products.
Despite the revenue beat and raised FY guidance, the stock is down 7% pre-market due to concerns about the company's profit outlook and declining gross margins.

Analysts· Jul 1

Bank of America raised its price target for Hims & Hers Health to $36 from $25, maintaining a Hold rating.
Canaccord Genuity raised its price target for Hims & Hers Health to $40 from $32, maintaining a Buy rating.
Analysts are upgrading their price targets for Hims & Hers Health due to improving prescription trends, growing demand for GLP-1 treatments, and continued enthusiasm, with two firms raising targets while the stock was already rising.

Announcements· Aug 11

Hims & Hers Health, Inc. (HIMS) reported Q2 revenue of $753.2M, a 38% YoY increase, beating expectations and adding 300,000 new subscribers.
The company's international business is expanding, with the U.K., Australia, and Germany each generating more than $100M in annualized revenue, and Canada on track to join this group.
HIMS raised its full-year revenue guidance to $3.1-$3.3B, driven by the Eucalyptus acquisition and strong growth in its weight-loss business, but also reported a net loss of $0.37/share due to declining gross margins.

Controversies· Jul 30

The FTC has sued Hims & Hers Health for alleged privacy and billing practices, with the company claiming the claims are baseless and planning to fight them.
Hims & Hers has been under FTC investigation for years, with the investigation becoming a lawsuit yesterday, and the company's disclosure of this information may have contributed to its stock price drop.
The lawsuit against Hims & Hers may be an overhang on the stock, with the FTC alleging that the company shared sensitive health data with advertisers without proper consent.

Macro· May 12

Hims & Hers Health reported Q1 2026 earnings with a significant miss on revenue and EPS, but the company's underlying story is a massive strategic shift toward branded GLP-1 medications.
The company's telehealth growth story is over, replaced by a narrative of rising customer acquisition costs, declining revenue per user, and margin compression.
Despite missing earnings estimates, the company's revenue and subscriber growth suggest a potential turnaround in 2026, but market sentiment currently ignores this narrative.

Technical Analysis· Aug 19

$HIMS is approaching a test of the 50 WMA at a time when the weekly moving averages are starting to squeeze, and a big move is coming for this stock, with a move above $33 potentially triggering a rapid move higher.
The stock is currently basing around the yearly-low AVWAP, where it meets the curved trendline, and is squeezed between two big levels pulling opposite ways, with $30 being the biggest calming node.
$HIMS has been in a bullish trend, breaking above the $30 level after a strong move, and is expected to continue moving higher, but patience is required, as great companies can still test one's conviction, and volatility is part of the game.

Generated by AI

Community

Of the messages about HIMS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.73%	76.7%	43.96%	68.1%
Newcomers	12.27%	23.3%	56.04%	31.9%

Regulars· Sep 29

The biology revolution is expected to be delivered through Hims & Hers Health, Inc. ($HIMS), with many regulars holding onto their shares despite recent price swings.
Hims & Hers Health, Inc. ($HIMS) has reported a year-over-year increase of $84.5M in US quarterly revenue, with some arguing that the business has strong demand.
The subscriber/ARPU (average revenue per user) model for Hims & Hers Health, Inc. ($HIMS) has been updated, showing a Q3 subscriber count of 3.191M and an ARPU of $100, but with challenges in modeling and backtesting due to recent additions and relaunches.

Newcomers· Sep 29

Newcomers are excited about the potential for $HIMS to become a popular "memecoin" due to its stock price movement and pairing with other assets.
Fresh contract wins and revenue traction are being watched closely by newcomers, who are optimistic about the company's ability to scale and convert these wins into recognized revenue.
Newcomers are also discussing the long-term biology angle and how $HIMS is a direct way to play this theme, with some expressing interest in the company's ability to execute and convert its backlog into revenue.

Generated by AI

Hims & Hers Health

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 23

Earnings· Aug 11

Analysts· Jul 1

Announcements· Aug 11

Controversies· Jul 30

Macro· May 12

Technical Analysis· Aug 19

Regulars· Sep 29

Newcomers· Sep 29

Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit

INVESTOR ALERT: Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hims & Hers Stock: 30% Growth Can’t Hide a Margin Problem

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit

Can Hims & Hers Health (HIMS) Stay Cheap As Sales Face Scrutiny?

Hims & Hers CFO Okupe sells $876,846 of HIMS stock

Also Discussed

Hims & Hers Health, Inc.

Company Information

Location

Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit

INVESTOR ALERT: Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hims & Hers Stock: 30% Growth Can’t Hide a Margin Problem

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit

Can Hims & Hers Health (HIMS) Stay Cheap As Sales Face Scrutiny?

Hims & Hers CFO Okupe sells $876,846 of HIMS stock

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 23

Earnings· Aug 11

Analysts· Jul 1

Announcements· Aug 11

Controversies· Jul 30

Macro· May 12

Technical Analysis· Aug 19

Regulars· Sep 29

Newcomers· Sep 29